193 related articles for article (PubMed ID: 23200914)
1. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.
Cope L; Wu RC; Shih IeM; Wang TL
Gynecol Oncol; 2013 Mar; 128(3):500-5. PubMed ID: 23200914
[TBL] [Abstract][Full Text] [Related]
2. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
[TBL] [Abstract][Full Text] [Related]
3. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
4. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
5. High levels of genomic aberrations in serous ovarian cancers are associated with better survival.
Baumbusch LO; Helland Å; Wang Y; Liestøl K; Schaner ME; Holm R; Etemadmoghadam D; Alsop K; Brown P; ; Mitchell G; Fereday S; DeFazio A; Bowtell DD; Kristensen GB; Lingjærde OC; Børresen-Dale AL
PLoS One; 2013; 8(1):e54356. PubMed ID: 23372714
[TBL] [Abstract][Full Text] [Related]
6. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA; George J; Fereday S; Loehrer E; Van Loo P; Cullinane C; Etemadmoghadam D; Ftouni S; Galletta L; Anglesio MS; Hendley J; Bowes L; Sheppard KE; Christie EL; Pearson RB; Harnett PR; Heinzelmann-Schwarz V; Friedlander M; McNally O; Quinn M; Campbell P; deFazio A; Bowtell DD;
Cancer Res; 2012 Aug; 72(16):4060-73. PubMed ID: 22896685
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
Sato M; Sato S; Shintani D; Hanaoka M; Ogasawara A; Miwa M; Yabuno A; Kurosaki A; Yoshida H; Fujiwara K; Hasegawa K
BMC Cancer; 2022 Jan; 22(1):59. PubMed ID: 35027024
[TBL] [Abstract][Full Text] [Related]
8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
9. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract][Full Text] [Related]
10. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
11. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
[TBL] [Abstract][Full Text] [Related]
12. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing.
Cybulska P; Stewart JM; Sayad A; Virtanen C; Shaw PA; Clarke B; Stickle N; Bernardini MQ; Neel BG
Am J Pathol; 2018 May; 188(5):1120-1131. PubMed ID: 29458007
[TBL] [Abstract][Full Text] [Related]
13. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
15. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.
Skirnisdottir I; Mayrhofer M; Rydåker M; Akerud H; Isaksson A
BMC Cancer; 2012 Sep; 12():407. PubMed ID: 22967087
[TBL] [Abstract][Full Text] [Related]
16. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
Cuello MA; Kato S; Liberona F
J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
[TBL] [Abstract][Full Text] [Related]
17. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
18. Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
Kobayashi H; Ogawa K; Kawahara N; Iwai K; Niiro E; Morioka S; Yamada Y
Free Radic Res; 2017 Oct; 51(9-10):755-764. PubMed ID: 28931330
[TBL] [Abstract][Full Text] [Related]
19. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
20. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
Sung CO; Song IH; Sohn I
Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
